Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
7
RAFLF Quote, Financials, Valuation and Earnings
Last price:
$0.72
Seasonality move
:
0.2%
Day range:
$0.72 - $0.72
52-week range:
$0.60 - $0.83
Dividend yield:
2.6%
P/E ratio:
27.80x
P/S ratio:
2.32x
P/B ratio:
2.12x
Volume:
--
Avg. volume:
695
1-year change:
7.05%
Market cap:
$1.3B
Revenue:
$562.4M
EPS (TTM):
$0.03
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RAFLF
Raffles Medical Group Ltd.
|
-- | -- | -- | -- | -- |
|
BMGL
Basel Medical Group Ltd.
|
-- | -- | -- | -- | -- |
|
GDTC
CytoMed Therapeutics Ltd.
|
$130K | -$0.04 | -- | -- | -- |
|
MNDR
Mobile-health Network Solutions
|
-- | -- | -- | -- | -- |
|
WVE
Wave Life Sciences Ltd.
|
$7.7M | -$0.31 | -78.95% | -36.52% | $19.80 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RAFLF
Raffles Medical Group Ltd.
|
$0.72 | -- | $1.3B | 27.80x | $0.02 | 2.6% | 2.32x |
|
BMGL
Basel Medical Group Ltd.
|
$1.05 | -- | $19.7M | 294.67x | $0.00 | 0% | 2.31x |
|
GDTC
CytoMed Therapeutics Ltd.
|
$1.77 | -- | $20.8M | -- | $0.00 | 0% | 120.01x |
|
MNDR
Mobile-health Network Solutions
|
$1.52 | -- | $1.9M | -- | $0.00 | 0% | 0.14x |
|
WVE
Wave Life Sciences Ltd.
|
$7.49 | $19.80 | $1.3B | -- | $0.00 | 0% | 11.43x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RAFLF
Raffles Medical Group Ltd.
|
4.78% | 0.948 | -- | 1.17x |
|
BMGL
Basel Medical Group Ltd.
|
-- | 0.000 | -- | -- |
|
GDTC
CytoMed Therapeutics Ltd.
|
-- | -0.681 | -- | -- |
|
MNDR
Mobile-health Network Solutions
|
-- | -0.831 | -- | 2.20x |
|
WVE
Wave Life Sciences Ltd.
|
12.99% | 1.535 | 1.67% | 2.40x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RAFLF
Raffles Medical Group Ltd.
|
-- | -- | 5.84% | 6.17% | -- | -- |
|
BMGL
Basel Medical Group Ltd.
|
-- | -- | -- | -- | -- | -- |
|
GDTC
CytoMed Therapeutics Ltd.
|
-- | -- | -- | -- | -- | -- |
|
MNDR
Mobile-health Network Solutions
|
-- | -- | -1223.46% | -1223.46% | -- | -- |
|
WVE
Wave Life Sciences Ltd.
|
$5.4M | -$56.4M | -64.6% | -73.8% | -740.71% | -$46.1M |
Raffles Medical Group Ltd. vs. Competitors
-
Which has Higher Returns RAFLF or BMGL?
Basel Medical Group Ltd. has a net margin of -- compared to Raffles Medical Group Ltd.'s net margin of --. Raffles Medical Group Ltd.'s return on equity of 6.17% beat Basel Medical Group Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RAFLFRaffles Medical Group Ltd.-- -- $851.1M BMGLBasel Medical Group Ltd.-- -- -- -
What do Analysts Say About RAFLF or BMGL?
Raffles Medical Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Basel Medical Group Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Raffles Medical Group Ltd. has higher upside potential than Basel Medical Group Ltd., analysts believe Raffles Medical Group Ltd. is more attractive than Basel Medical Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RAFLFRaffles Medical Group Ltd.0 0 0 BMGLBasel Medical Group Ltd.0 0 0 -
Is RAFLF or BMGL More Risky?
Raffles Medical Group Ltd. has a beta of 0.204, which suggesting that the stock is 79.644% less volatile than S&P 500. In comparison Basel Medical Group Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RAFLF or BMGL?
Raffles Medical Group Ltd. has a quarterly dividend of $0.02 per share corresponding to a yield of 2.6%. Basel Medical Group Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Raffles Medical Group Ltd. pays 74.63% of its earnings as a dividend. Basel Medical Group Ltd. pays out -- of its earnings as a dividend. Raffles Medical Group Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RAFLF or BMGL?
Raffles Medical Group Ltd. quarterly revenues are --, which are smaller than Basel Medical Group Ltd. quarterly revenues of --. Raffles Medical Group Ltd.'s net income of -- is lower than Basel Medical Group Ltd.'s net income of --. Notably, Raffles Medical Group Ltd.'s price-to-earnings ratio is 27.80x while Basel Medical Group Ltd.'s PE ratio is 294.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Raffles Medical Group Ltd. is 2.32x versus 2.31x for Basel Medical Group Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAFLFRaffles Medical Group Ltd.2.32x 27.80x -- -- BMGLBasel Medical Group Ltd.2.31x 294.67x -- --
-
Which has Higher Returns RAFLF or GDTC?
CytoMed Therapeutics Ltd. has a net margin of -- compared to Raffles Medical Group Ltd.'s net margin of --. Raffles Medical Group Ltd.'s return on equity of 6.17% beat CytoMed Therapeutics Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RAFLFRaffles Medical Group Ltd.-- -- $851.1M GDTCCytoMed Therapeutics Ltd.-- -- -- -
What do Analysts Say About RAFLF or GDTC?
Raffles Medical Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand CytoMed Therapeutics Ltd. has an analysts' consensus of -- which suggests that it could grow by 182.49%. Given that CytoMed Therapeutics Ltd. has higher upside potential than Raffles Medical Group Ltd., analysts believe CytoMed Therapeutics Ltd. is more attractive than Raffles Medical Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RAFLFRaffles Medical Group Ltd.0 0 0 GDTCCytoMed Therapeutics Ltd.0 0 0 -
Is RAFLF or GDTC More Risky?
Raffles Medical Group Ltd. has a beta of 0.204, which suggesting that the stock is 79.644% less volatile than S&P 500. In comparison CytoMed Therapeutics Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RAFLF or GDTC?
Raffles Medical Group Ltd. has a quarterly dividend of $0.02 per share corresponding to a yield of 2.6%. CytoMed Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Raffles Medical Group Ltd. pays 74.63% of its earnings as a dividend. CytoMed Therapeutics Ltd. pays out -- of its earnings as a dividend. Raffles Medical Group Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RAFLF or GDTC?
Raffles Medical Group Ltd. quarterly revenues are --, which are smaller than CytoMed Therapeutics Ltd. quarterly revenues of --. Raffles Medical Group Ltd.'s net income of -- is lower than CytoMed Therapeutics Ltd.'s net income of --. Notably, Raffles Medical Group Ltd.'s price-to-earnings ratio is 27.80x while CytoMed Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Raffles Medical Group Ltd. is 2.32x versus 120.01x for CytoMed Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAFLFRaffles Medical Group Ltd.2.32x 27.80x -- -- GDTCCytoMed Therapeutics Ltd.120.01x -- -- --
-
Which has Higher Returns RAFLF or MNDR?
Mobile-health Network Solutions has a net margin of -- compared to Raffles Medical Group Ltd.'s net margin of --. Raffles Medical Group Ltd.'s return on equity of 6.17% beat Mobile-health Network Solutions's return on equity of -1223.46%.
Company Gross Margin Earnings Per Share Invested Capital RAFLFRaffles Medical Group Ltd.-- -- $851.1M MNDRMobile-health Network Solutions-- -- $4.1M -
What do Analysts Say About RAFLF or MNDR?
Raffles Medical Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Mobile-health Network Solutions has an analysts' consensus of -- which suggests that it could grow by 20952.63%. Given that Mobile-health Network Solutions has higher upside potential than Raffles Medical Group Ltd., analysts believe Mobile-health Network Solutions is more attractive than Raffles Medical Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RAFLFRaffles Medical Group Ltd.0 0 0 MNDRMobile-health Network Solutions0 0 0 -
Is RAFLF or MNDR More Risky?
Raffles Medical Group Ltd. has a beta of 0.204, which suggesting that the stock is 79.644% less volatile than S&P 500. In comparison Mobile-health Network Solutions has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RAFLF or MNDR?
Raffles Medical Group Ltd. has a quarterly dividend of $0.02 per share corresponding to a yield of 2.6%. Mobile-health Network Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Raffles Medical Group Ltd. pays 74.63% of its earnings as a dividend. Mobile-health Network Solutions pays out -- of its earnings as a dividend. Raffles Medical Group Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RAFLF or MNDR?
Raffles Medical Group Ltd. quarterly revenues are --, which are smaller than Mobile-health Network Solutions quarterly revenues of --. Raffles Medical Group Ltd.'s net income of -- is lower than Mobile-health Network Solutions's net income of --. Notably, Raffles Medical Group Ltd.'s price-to-earnings ratio is 27.80x while Mobile-health Network Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Raffles Medical Group Ltd. is 2.32x versus 0.14x for Mobile-health Network Solutions. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAFLFRaffles Medical Group Ltd.2.32x 27.80x -- -- MNDRMobile-health Network Solutions0.14x -- -- --
-
Which has Higher Returns RAFLF or WVE?
Wave Life Sciences Ltd. has a net margin of -- compared to Raffles Medical Group Ltd.'s net margin of -707.83%. Raffles Medical Group Ltd.'s return on equity of 6.17% beat Wave Life Sciences Ltd.'s return on equity of -73.8%.
Company Gross Margin Earnings Per Share Invested Capital RAFLFRaffles Medical Group Ltd.-- -- $851.1M WVEWave Life Sciences Ltd.70.69% -$0.32 $152.2M -
What do Analysts Say About RAFLF or WVE?
Raffles Medical Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Wave Life Sciences Ltd. has an analysts' consensus of $19.80 which suggests that it could grow by 164.35%. Given that Wave Life Sciences Ltd. has higher upside potential than Raffles Medical Group Ltd., analysts believe Wave Life Sciences Ltd. is more attractive than Raffles Medical Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RAFLFRaffles Medical Group Ltd.0 0 0 WVEWave Life Sciences Ltd.13 1 0 -
Is RAFLF or WVE More Risky?
Raffles Medical Group Ltd. has a beta of 0.204, which suggesting that the stock is 79.644% less volatile than S&P 500. In comparison Wave Life Sciences Ltd. has a beta of -1.719, suggesting its less volatile than the S&P 500 by 271.88%.
-
Which is a Better Dividend Stock RAFLF or WVE?
Raffles Medical Group Ltd. has a quarterly dividend of $0.02 per share corresponding to a yield of 2.6%. Wave Life Sciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Raffles Medical Group Ltd. pays 74.63% of its earnings as a dividend. Wave Life Sciences Ltd. pays out -- of its earnings as a dividend. Raffles Medical Group Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RAFLF or WVE?
Raffles Medical Group Ltd. quarterly revenues are --, which are smaller than Wave Life Sciences Ltd. quarterly revenues of $7.6M. Raffles Medical Group Ltd.'s net income of -- is lower than Wave Life Sciences Ltd.'s net income of -$53.9M. Notably, Raffles Medical Group Ltd.'s price-to-earnings ratio is 27.80x while Wave Life Sciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Raffles Medical Group Ltd. is 2.32x versus 11.43x for Wave Life Sciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAFLFRaffles Medical Group Ltd.2.32x 27.80x -- -- WVEWave Life Sciences Ltd.11.43x -- $7.6M -$53.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
50
TGL alert for Dec 8
Treasure Global, Inc. [TGL] is up 3.46% over the past day.
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 47.95% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 10.69% over the past day.
